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RESEARCH PAPER
Risk factors for early psychosis in PD: insights from
the Parkinson’s Progression Markers Initiative
Dominic H ffytche,1,2 Joana B Pereira,3 Clive Ballard,1,4 K Ray Chaudhuri,1,5
Daniel Weintraub,1,6,7,8 Dag Aarsland1,2,9
ABSTRACT
Background Parkinson’s Disease (PD) psychosis refers
to the spectrum of illusions, formed hallucinations and
delusions that occur in PD. Visual hallucinations and
illusions are thought to be caused by speciﬁc cognitive
and higher visual function deﬁcits and patients who
develop such symptoms early in the disease course have
greater rates of cognitive decline and progression to
dementia. To date, no studies have investigated whether
such deﬁcits are found prior to the onset of PD
psychosis.
Method Here we compare baseline cognitive,
biomarker (structural imaging and cerebrospinal ﬂuid)
and other PD psychosis risk factor data in patients who
go on to develop illusions or hallucinations within 3–4
years of follow-up in the Parkinson’s Progression
Markers Initiative cohort of newly diagnosed PD.
Results Of n=423 patients with PD, n=115 (27%)
reported predominantly illusions with the median time of
onset at 19.5 months follow-up. At study entry these
patients had reduced CSF amyloid Aß1-42, lower olfaction
scores, higher depression scores and increased REM
sleep behaviour disorder symptoms compared to patients
without early onset PD psychosis but no differences in
cognitive, higher visual or structural imaging measures.
A subset of patients with early onset formed
hallucinations (n=21) had reduced higher visual function
at baseline, cortical thinning in parietal, occipital and
frontal cortex and reduced hippocampal volume.
Conclusions The ﬁndings suggest early onset illusions
and formed hallucinations are linked to amyloid
pathology in PD and point to a difference in the
underlying pathophysiological mechanism of illusions
and formed hallucinations, with implications for their
respective links to future cognitive decline.
INTRODUCTION
Parkinson’s disease (PD) psychosis refers to a spec-
trum of symptoms that occur at different disease
stages.1 2 Minor symptoms occurring early in PD
include visual illusions (a real object perceived
incorrectly), passage hallucinations (a hallucinated
animal or ﬁgure passing in the peripheral visual
ﬁeld) and presence hallucinations (the sense of
someone nearby). In some patients, such experi-
ences precede the onset of motor symptoms.3 As
PD progresses, formed visual hallucinations occur
with preserved insight (recognition that the experi-
ences are not real). In later PD stages, insight may
become lost with the development of false explana-
tions about the experiences (secondary delusions),
hallucinations in other sensory modalities (auditory,
tactile or olfactory), delusions (eg, themes of guilt
or grandiosity4) and misidentiﬁcation syndromes
(eg, the belief that someone familiar has been
replaced by an imposter5). Such symptoms are an
important treatment priority as they precipitate the
move into a care home from living independently6 7
and impact on quality of life.8
Alongside clinical considerations, PD psychosis is
emerging as an important biomarker of disease pro-
gression and cognitive outcome. Although most PD
patients will develop hallucinations as disease pro-
gresses, an estimated 60% experiencing PD psych-
osis by 12 years,9 a distinction can be made
between patients who develop such symptoms early
in the disease course and those who develop it in
later stages. Several studies have found visual hallu-
cinations predict later dementia or greater cognitive
decline.10–13 The underlying mechanism of this
association is unclear, but cross-sectional studies
have identiﬁed higher visual function deﬁcits in
domains such as object and visuospatial perception
and cognitive deﬁcits in domains of attention,
memory and executive function in PD patients with
visual hallucinations compared with those without
them.14 These deﬁcits of visual perception and
attentional control are thought to cause visual hal-
lucinations and illusions through an imbalance of
top-down expectations and bottom-up visual pro-
cessing (see ref. 15 for a review). Consistent with
the neuropsychological ﬁndings, visual hallucina-
tions are associated with reduced grey matter
volume in the visual system, hippocampus, frontal
regions (particularly lateral frontal cortex) and
cerebellum.16–20 Lewy bodies, amyloid and tau
pathologies are found at postmortem in some of
these regions in PD patients with a history of visual
hallucinations,21 although such pathology is
notably absent in the cortex and hippocampus of
non-demented PD patients with visual
hallucinations.22
While the link between formed hallucinations
and visual and cognitive deﬁcits is clear, what is
less certain is whether the same is true of illusions,
the earliest symptoms of PD psychosis. Patients
with illusions, presence and passage hallucinations
do not have signiﬁcant differences in verbal
memory, verbal ﬂuency or sustained attention com-
pared with patients without such symptoms23 and
the only regions of cortical volume loss identiﬁed
in an imaging study of early symptoms were in the
midbrain, cerebellar vermis and visual parietal
cortex.24 Furthermore, other risk factors for PD
psychosis have been identiﬁed whose role is
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unclear, including rapid eye movement (REM) sleep behaviour
disorder (see ref. 25 for a review), depression26 and dopamine
agonist medication.9 13 Such ﬁndings raise the possibility that
the earliest symptoms of PD psychosis may differ in their aetio-
logical cause to later symptoms. Here, we explore this issue and
the wider implications of early-onset and late-onset PD psych-
osis by examining the proﬁle of cognitive, biomarker (structural
imaging and cerebrospinal ﬂuid (CSF)) and other risk factors
prior to the onset of illusions and hallucinations in the
Parkinson’s Progression Markers Initiative (PPMI) data set.27
METHODS
The Parkinson’s Progression Markers Initiative (PPMI)27 is an
observational multicentre study of newly diagnosed, drug-naïve
patients and healthy controls using standardised, clinical,
imaging, CSF and cognitive assessments at 3-month intervals in
the ﬁrst year and 6-month intervals in subsequent years (http://
www.ppmi-info.org/). The analysis reported here was performed
on the PPMI data set completed up to 15 January 2016 contain-
ing n=195 healthy controls and n=423 PD patients based on
clinical and DAT scan criteria (patients classiﬁed as having scans
without evidence for dopaminergic deﬁcit are not included in
the analysis). At the time of download, 70% of PD patients and
100% of healthy controls had been followed for 3 years or
more. Subsets of the PD and healthy control groups were
created for the analysis as described below.
Ethics Each participating PPMI site received approval from an
ethical standards committee on human experimentation before
study initiation and written informed consent for research was
obtained from all participants in the study.
Group deﬁnitions
PD patients were divided into groups based on the subsequent
development of PD psychosis during PPMI follow-up using the
UPDRS part 1 hallucinations/psychosis item. The item cate-
gorises symptoms experienced over the preceding week into 5
levels: 0, no symptoms; 1, minor illusions and non-formed hal-
lucinations; 2, formed hallucinations with preserved insight; 3,
formed hallucinations without insight; 4, psychosis with delu-
sions and hallucinations. Four groups were deﬁned:
▸ HC Healthy controls.
▸ PD-Psy0 PD patients without reports of psychosis symptoms
at any assessment. An arbitrary minimum period of follow-up
(18 months) was used as an additional inclusion criterion to
exclude patients for whom the presence or absence of
early-onset PD psychosis symptoms was, as yet, unknown.
▸ PD-Psy1+ PD patients reporting any PD psychosis symptom
graded 1 or more on the UPDRS hallucinations/psychosis
item at one or more assessments.
▸ PD-Psy2+ A subgroup of patients in the PD-Psy1+ group
reporting symptoms graded 2 or more on the UPDRS hallu-
cinations/psychosis item at one or more assessments.
Assessments
Cognitive function measures The Montreal Cognitive
Assessment (MoCA) assessed general cognitive abilities
(maximum value=30). Mild cognitive impairment in PD
(PD-MCI) was assessed using level 1 criteria of MoCA score
<26.28 Executive function was assessed using semantic ﬂuency
(the sum of item names per minute in the animal, vegetable and
fruit categories). Verbal memory was assessed using the Hopkins
Verbal Learning Test delayed recall score (20 min delay;
maximum score=12). Visuospatial function was assessed using
the Benton Judgement of Line Orientation (maximum
value=15). Attention was assessed using Letter Number
Sequencing (maximum=21).
Motor assessments
Motor symptoms were assessed using the UPDRS part 3 motor
subscale.
Other risk factors REM Sleep Behaviour Disorder Screening
Questionnaire (maximum=12). Geriatric Depression Scale
(maximum=15; higher score lower mood). As decreased olfac-
tion score has been associated with cognitive decline in the
PPMI data set,29 the University of Pennsylvania Smell
Identiﬁcation Test was also included in the analysis (UPSIT;
maximum score 40).
Structural imaging T1-weighted images were acquired on a 3 T
Siemens scanner using a magnetisation-prepared rapid-acquisition
gradient echo sequence. For details on the PPMI MRI protocol,
see Pereira et al.30 A subset of PD patients and healthy controls
had baseline MRI data of sufﬁcient quality to estimate cortical
thickness (HC=48; PD-Psy0=87; PD-Psy1+=31; PD-Psy2+=9).
As the number of patients with usable baseline scans in each group
was small, to maximise numbers and differences between groups,
the PD-Psy2+ subset of patients was not included in the
PD-Psy1+group and 6 patients in the PD-Psy0 group that had
withdrawn before 18 months follow-up were included in the ana-
lysis. Images were preprocessed and analysed using Freesurfer
(V.5.3, http://freesurfer.net/) to: (1) generate a cortical surface
model estimating cortical thickness at each vertex, smoothed with
a 15 mm FWHM kernel and (2) estimate the volume of subcor-
tical grey matter structures.
CSF methods Details of the PPMI CSF sampling and analysis
procedures are described on the study website (http://www.
ppmi-info.org/). CSF Aβ1-42, total tau, p-tau1818 and
α-synuclein values were used in the analysis. As α-synuclein is
present in red blood cells, CSF haemoglobin was examined as a
measure of CSF blood contamination.
Statistical analysis
Baseline demographic, PD motor, cognitive and non-cognitive
data were compared using t-tests, non-parametric or χ2 tests as
appropriate within SPSS V.20. Differences in cortical thickness
between groups were assessed using Qdec within FreeSurfer
with Monte Carlo simulations (p<0.05), while controlling for
the effects of age, gender, education, presence of PD-MCI (see
ref. 30 for criteria), UPDRS motor scores (when appropriate),
differences in scanner site and software. Differences in subcor-
tical grey matter volumes were evaluated using an analysis of
covariance in SPSS, while controlling for the covariates above in
addition to intracranial volume as estimated by FreeSurfer.
RESULTS
At the time of data download, n=115 (27%) PD patients had
reported psychosis symptoms in one or more of the PPMI
follow-up assessments over 4 years (PD-Psy1+ group). By com-
parison, only n=3 (1%) patients in the Healthy Control group
reported any psychosis spectrum symptom. A subset of PD
psychosis patients in whom no PD psychosis symptoms had
been reported in any follow-up assessment was identiﬁed
(PD-Psy0, n=286; 72% of the group had 3 years or more
without PD psychosis symptoms) as well as a subset of healthy
controls with 3 years follow-up (HC, n=144).
PD psychosis symptom onset and course
Figure 1 shows the number of patients in the PD-Psy1+ group
over the 4-year follow-up period. The median time to the ﬁrst
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PD psychosis symptom was 19.5 months. The majority of
patients in the PD-Psy1+ group (81%) reported only illusions
at any assessment (all UPDRS hallucination/psychosis
scores=1). Fifty-eight per cent of PD-Psy1+ had two or more
assessments with PD psychosis symptoms. A subgroup of
PD-Psy1+ patients (PD-Psy2+, n=21) reported formed halluci-
nations or delusions at one or more assessments (one or more
UPDRS hallucination/psychosis scores=2, 3 or 4). Of these
patients, n=16 reported illusions on some assessments and
formed hallucinations on others (illusions preceded formed hal-
lucinations in n=9).
Table 1 shows demographic and risk factor characteristics at
study entry for each group. There are no differences between
PD patients without (PD-Psy0) and with early-onset psychosis
spectrum symptoms (PD-Psy1+ or PD-Psy2+) on demographic
or PD motor measures. RBD score, depression score and olfac-
tion score differed between patients with and without
early-onset PD psychosis (all p<0.05). There were no differ-
ences in cognitive measures between PD-Psy0 and PD-Psy1+
or the proportion of patients meeting level-1 criteria for
PD-MCI.28 PD-Psy2+ had signiﬁcantly reduced performance
in the Benton Judgement of Line Orientation task compared
with PD-Psy0. Consistent with previous studies, verbal ﬂuency
was reduced in PD-Psy2+ compared with PD-Psy0, although
only at trend signiﬁcance (p=0.07). We also looked for differ-
ences in cognitive scores in the period immediately before the
onset of PD psychosis. Figure 2 shows the time course of
MoCA score prior to PD psychosis onset (black circle) in
patients with symptom onset at 1 year (green line), 2 years (red
line) and 3 years (blue line) after study entry and the PD-Psy0
group (black line). Using a mixed model ANOVA with ﬁxed
factors TIME (months prior to hallucination onset in PD-Psy1
+ or months after study entry in PD-Psy0) and GROUP
(PD-PSy0, PD-Psy1+), we found no signiﬁcant effect of
GROUP (p>0.05) or a TIME by GROUP interaction
(p>0.05) suggesting MoCA score or MoCA score decline
prior to the onset of PD psychosis were equivalent in the
PD-Psy0 and PD-Psy1+ groups. There were no TIME by
GROUP interactions for ﬂuency, Hopkins Verbal Learning,
Benton Judgement of Line Orientation or Letter Number
Sequencing (all p>0.05).
Figure 1 Number of Parkinson’s disease (PD) patients in the PD Psy1
+ group at each follow-up assessment. Y-axis scaled to total number of
patients with PD at study entry (n=423). The red line indicates the
number of patients that had completed baseline, 1 year, 2 year and 3
year assessments at the time of data download. The percentage of
patients with PD psychosis symptoms may increase as further follow-up
data is collected.
Table 1 Baseline demographic Parkinson’s disease motor, cognitive and other measures in each group
HC PD-Psy0 PD-Psy1+ PD-Psy2+
n=144 n=286 n=115 n=21
Demographic
Age (years) 59.79±11.5 61.97±9.9 60.77±9.6 64.43±7.5
Gender M=60% M=67% M=62% M=71%
PD
Duration (months) 6.51±6.3 6.92±7.2 8.52±7.2
UPDRS part 111 1.33±2.4 21.1±8.8 20.08±9.0 21.90±7.6
Tremor onset % 79 75 76
Bradykinesia onset % 81 87 85
Rigidity onset % 77 74 76
Postural onset % 7 6 9
Other onset % 17 16 14
Left/symmetric onset 43 47 47
Non-cognitive
RBD 2.66±2.0 2.91±2.5 3.97±2.8 5.38±3.4
Olfaction 33.95±4.7 22.78±8.2 21.02±8.0 17.9±7.3
GDS 1.31±2.2 2.18±2.4 2.72±2.5 4.24±3.3
Cognitive
MoCA 28.2±1.0 27.1±2.3 27.16±2.3 26.29±3.0
PD-MCI 24% 18% 28%
Fluency 52.1±11.2 48.58±11.6 48.11±11.4 43.86±11.2*
Hopkins delay 9.27±2.3 8.26±2.5 8.65±2.4 7.71±3.0
Benton line 13.11±2.0 12.93±2.0 12.60±2.2 11.76±2.5
Letter number 10.97±2.5 10.52±2.6 10.68±2.6 9.8±2.9
Shaded cells indicate group comparisons between PD-Psy0 and PD-Psy1+ or PD-Psy2+ significant at p<0.05 (t-tests for independent samples).
*p=0.07 trend significance.
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PD psychosis and medication for PD
Patients at PPMI study entry are not taking medication which is
only added when clinically appropriate. If the onset of PD
psychosis is linked to PD medication, one might expect a higher
proportion of patients with PD psychosis to be taking medica-
tion at any given time. As shown in table 2, a similar proportion
of patients with and without early-onset PD psychosis are pre-
scribed any medication for PD, L-Dopa or a Dopamine agonist
in each follow-up period. Across all time points, the only signiﬁ-
cant difference was found at 24 months where a higher propor-
tion of PD-Psy1+ was prescribed dopamine agonists. There is
no difference between PD-Psy0 and PD-Psy1+ groups in the
time from PD diagnosis to starting any PD medication or to
starting a dopamine agonist (both p>0.05) (table 3). Surgical
treatment for PD using deep brain stimulation (DBS) had been
started in seven patients during follow-up (36–54 months after
study entry; n=4 in PD-Psy0; n=3 in PD-Psy1+). Illusions pre-
ceded DBS in all three PD-Psy1+ patients by a minimum of
2 years. There is currently insufﬁcient post-DBS follow-up evi-
dence to comment on whether DBS improves or exacerbates PD
psychosis symptoms.
Structural imaging
No signiﬁcant differences in baseline cortical thickness were
found between PD-Psy0 and PD-Psy1+ or between healthy con-
trols and PD-Psy1+. However, compared with PD-Psy0, the
PD-Psy2+ group had reduced cortical thickness in the right
hemispheric frontal, occipital, parietotemporal (supramarginal
gyrus) and insula regions and reduced volumes bilaterally in the
basal ganglia and hippocampus (ﬁgure 3 and table 4).
Cerebrospinal ﬂuid
Patients with early-onset PD psychosis (PD-Psy1+ and PD-Psy2+
groups) had decreased baseline CSFAβ1-42 compared with patients
without PD psychosis (PD-PSy0) (see table 5; MoCA score is
equivalent across groups and has therefore not been included as a
covariate in the analysis). There were no group differences in the
levels of total tau, p-tau181 and α-synuclein. Red blood cell con-
tamination as measured by haemoglobin concentration was
evident but equivalent in patients with and without PD psychosis
(p>0.05; Mann-Whitney U test).
DISCUSSION
This is one of the ﬁrst studies exploring clinical and imaging
risk factors for early psychosis in a large cohort of de novo PD
patients. In the PPMI data set, ﬁrst-onset PD psychosis symp-
toms were reported at some point during 4 years of follow-up
in 27% of PD patients. While the clinical and cognitive out-
comes of these patients will be assessed at study completion,
questions related to the onset of PD psychosis symptoms can be
addressed in data already available. In what follows, we discuss
our ﬁndings in relation to the aetiological mechanism of
early-onset PD psychosis and its prognostic implications.
CSF Aβ1-42 and PD psychosis
We found an association between early-onset PD psychosis and
reduced Aβ1-42,, but not with total tau, p-tau or α-synuclein. PD
psychosis in later disease stages has been linked to higher levels
of amyloid, tau and α-synuclein pathology in frontal, parietal
and hippocampal areas21 and our ﬁnding may suggest
early-onset PD psychosis is a biomarker for the subsequent
development of Alzheimer pathology. Previous studies of the
PPMI cohort have found reduced Aβ1-42 (but not total tau) asso-
ciated with PD-MCI and reduced α-synuclein associated with
executive dysfunction.31 A link between Aβ1-42, PD-MCI and
early-onset PD psychosis might explain the poor longer term
cognitive outcomes found in previous studies of visual hallucina-
tions, although the relationship with PD-MCI is complex as the
proportion of patients with PD-MCI did not differ between
groups with and without PD psychosis in our data. Lower olfac-
tion scores have also been associated with lower Aβ1-42 in the
PPMI data set29 and our ﬁndings suggest the olfaction changes
are also associated with subsequent development of PD psych-
osis. The neurobiological signiﬁcance of this association is
unclear.
Figure 2 Global cognition and the onset of Parkinson’s disease (PD)
psychosis. The MoCA score trajectory prior to onset of PD psychosis
(black circle) in subgroups of patients with PD psychosis onset at 1 year
(green line), 2 years (red line) and 3 years (blue line). The trajectory of
patients without PD psychosis (PD-Psy0) is shown in black. The slopes
of MoCA decline do not differ between groups with and without PD
psychosis (see text for further details).
Table 2 Parkinson’s disease (PD)-psychosis and medication for PD
% patients on medication Baseline (%) 12 months (%) 24 months (%) 36 months (%)
Any PD medication PD-Psy1+ 0 66 87 97
PD-Psy0 0 62 86 92
L-Dopa PD-Psy1+ 0 18 34 64
PD-Psy0 0 26 46 59
Dopamine agonist PD-Psy1+ 0 23 45* 41
PD-Psy0 0 23 29* 34
*χ2=p<0.01.
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Cognition, cortical changes and visual hallucinations
Cross-sectional studies of patients susceptible to visual hallucina-
tions typically ﬁnd deﬁcits of executive function, attention,
memory and visual perception (see ref. 14 for a review). We only
found evidence for deﬁcits in visuospatial processing (assessed
by the Benton Line Judgement test) and trend level deﬁcits in
executive function. The lack of prominent deﬁcits in other cog-
nitive domains may reﬂect the small number of patients with
formed hallucinations and differences in tests used in PPMI
compared with previous studies of visual hallucinations.
The deﬁcits of visual and cognitive function in PD patients
with visual hallucinations are thought to relate to volume loss in
frontal, parietal, limbic, occipital and hippocampal cortex (see
refs 32–34 for recent reviews). Here, we found evidence for these
structural changes in patients with de novo PD who go on to
develop formed hallucinations. A notable difference from previ-
ous studies was the lack of prominent involvement of dorsolat-
eral prefrontal cortex, inferior frontal cortex and ventral
occipitotemporal cortex. The underlying pathology of these cor-
tical and hippocampal changes is unclear as there is only sparse
cortical Lewy pathology in patients with preserved cognition22
equivalent to that in the PPMI cohort. The overall distribution
of cortical thinning found in patients with formed hallucinations
also differs from that associated with PD-MCI in the PPMI
cohort.30 Together with the control for PD-MCI status in our
MRI analysis, this suggests the distribution of cortical thinning
identiﬁed here may be speciﬁc to formed hallucinations.
Illusions and hallucinations: one aetiological
mechanism or two?
Given that illusions and formed hallucinations are thought to
share the same mechanism of dysfunctional top-down and
bottom-up integration,35 an unexpected ﬁnding was the lack of
cognitive differences or cortical thinning in the broadly deﬁned
PD psychosis group with predominantly illusions. This does not
seem to reﬂect cognitive decline between the time of assessment
and the time of symptom onset as there was no difference in the
trajectory of MoCA global cognitive decline between groups
before symptoms began. Although subtle cognitive and visual
perceptual changes at baseline or symptom onset cannot be
ruled out, the lack of difference between groups may suggest
illusions and other early phenomena in PD have an underlying
aetiological mechanism that differs from formed hallucinations.
In support of this view, previous studies have found that pres-
ence hallucinations are associated with sleep regulation and
somnolence scores while illusions are associated with somno-
lence and motor severity scores.36 These early symptoms have
been linked to brainstem, eye movement and motion perception
mechanisms in the visual parietal lobe24 37 rather than the
ventral occipitotemporal cortical regions thought to underlie
formed visual hallucinations.38 Our ﬁnding of increased REM
sleep behaviour disorder score in the group with predominantly
illusion symptoms is consistent with this view.
Other risk factors
We found a difference in the proportion of patients prescribed
dopamine agonists at 2 years consistent with previous ﬁndings from
the PPMI cohort.39 However, drug-naïve patients with PD psych-
osis in the PPMI cohort and other studies3 suggest that the onset of
PD psychosis is not directly related to starting PD medication. The
neurobiological interpretation of the association between higher
baseline depression scores and early-onset PD psychosis is also
unclear. An association between depression and illusions, passage
and presence hallucinations in PD has been described previously;40
however, the evidence presented here suggests that depressive symp-
toms are not merely a response to illusions as, in the majority of
patients, depression scores are elevated before illusion onset.
The timing of early-onset versus late-onset PD psychosis
As the prevalence of PD psychosis increases with disease duration,
a high proportion of PD patients will eventually develop such
symptoms. The distinction made in this study is between PD
patients with onset of symptoms within the ﬁrst 3–4 years of
PPMI follow-up and ‘late onset’ patients in whom PD psychosis
symptoms have not yet developed. The majority of the late-onset
group have remained without PD psychosis symptoms for 3 years
or more at the time of data download. Whether (or when) this
group will develop psychosis symptoms is currently unclear but
will help deﬁne the time window for late-onset PD psychosis.
Limitations
An important limitation to the study is the lack of phenomeno-
logical detail with respect to PD psychosis. For example, it is
Table 3 Parkinson’s disease-psychosis and time to medication
onset
PD medication onset (months
from diagnosis) PD-Psy0 PD-Psy1+
Any PD medication 21.1±11 (n=269) 22.1±11 (n=112)
Dopamine agonist 25.0±13 (n=136) 26.5±13 (n=77)
t-test for independent samples.
Figure 3 Baseline cortical thickness
differences between patients with
formed hallucinations (PD-Psy2+)
compared with those without
Parkinson’s disease (PD) psychosis
(PD-Psy0) on a surface rendered right
hemisphere in lateral (left panel) and
medial (right panel) view. Colour
coding indicates cluster signiﬁcance on
a logarithmic scale of p values
(−log10).
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unclear whether formed hallucinations are visual or involve
other sensory modalities or what symptoms are classed as illu-
sions. However, previous studies41 allow us to predict with con-
ﬁdence that the symptoms were visual. Another limitation is the
fact that information is only collected with respect to symptoms
in the week prior to a given assessment. Symptoms occurring
between assessments are thus missed in each group (although a
strength of the PPMI study is the short interval between assess-
ments in the ﬁrst year), so that prevalence estimates of PD
psychosis may be higher than those reported. The group distinc-
tions might therefore be better characterised as low (PD-Psy0)
and high (PD-Psy1+ and PD-Psy2+) rates of early-onset PD
psychosis rather than groups without and with early-onset PD
psychosis.
CONCLUSIONS
PD patients who develop illusions or hallucinations within 3–
4 years of PD diagnosis have CSF amyloid reduction, olfactory
impairment and increased depression and sleep behaviour scores
that predate PD psychosis onset. The neurobiological implica-
tions of these factors and how they relate to each other and to
prospective cognitive decline remain unclear. The ﬁndings also
suggest illusions and formed hallucinations indicate different pro-
ﬁles of visual, cognitive, cortical and hippocampal involvement
in PD. Patients who went on to develop formed hallucinations
had visual function deﬁcits, trend-level executive function deﬁ-
cits, widespread cortical thinning and hippocampal volume loss
at baseline compared with patients without early-onset symp-
toms, but no differences were found in patients who went on to
develop only illusions. If formed hallucinations imply the pres-
ence of neuropsychological deﬁcits, cortical thinning and hippo-
campal volume loss, their prognostic implication for cognitive
decline may differ from that of illusions. These differing bio-
marker implications highlight the need for scales and instruments
that distinguish between illusions, formed hallucinations and
other early symptoms in prospective studies of cognitive
outcome.
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